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Full clinical cases submission template 
 
TITLE OF CASE Do not include “a case report” 
Chronic inflammatory demyelinating polyneuropathy: a rare cause of falls 
 
SUMMARY Up to 150 words summarising the case presentation and outcome (this 
will be freely available online) 
This case of chronic inflammatory demyelinating polyneuropathy (CIDP) shows 
that a patient’s condition can evolve from the point of admission, gradually 
manifesting its underlying cause. Our patient’s initial presentation of backpain and 
lower limb weakness prompted investigations which ruled out compressive 
myelopathy and neuropathy. As upper limb weakness developed later, along with a 
more proximal and symmetrical pattern of lower limb weakness, the clinical 
picture suggested polyneuropathy. The diagnosis of CIDP became apparent only 
after numerous negative tests and nerve conduction studies identified 
demyelination. Diagnosing CIDP enabled the commencement of definitive 
treatment which led to a good recovery. 
 
 
 
BACKGROUND Why you think this case is important – why did you write it up? 
 
This case illustrates the importance of paying close attention to evolving signs and 
symptoms, and synthesising this information with data from investigations to 
arrive at a reasoned diagnosis. CIDP, because it frequently mimics other 
conditions, sometimes requires a complex work-up to diagnose definitively. 
Additionally, this case shows that common symptoms sometimes have uncommon 
causes. Considering of these ensures a thorough initial assessment, particularly 
examination, and should inform the differential diagnoses. Backpain and falls are 
common clinical presentations which call for a systematic and reasoned 
assessment. This is what is required to ensure minimal diagnostic delay and error 
and effective therapy. 
 
 
CASE PRESENTATION Presenting features, medical/social/family history 
A 71-year-old man was brought to the emergency department by ambulance after falling 
during an appointment with his general practitioner. He complained of five weeks of 
progressive leg weakness, intermittent lancinating lower back pain, and had fallen twice 
before attending his GP, when he had fallen for a third time. He explained that his legs had 
felt weak and had given out under him. He denied loss of consciousness, dizziness, 
palpitations, bladder or bowel disturbance and saddle anaesthesia. 
 
His medical background consisted of essential hypertension (medicated and controlled), 
recurrent inguinal hernia with previous repairs, previous non-ST elevation myocardial 
infarction and hypercholesterolemia. He took Amlodipine 10mg, Aspirin 75mg and 
Atorvastatin 80mg. 
 
He is a retired physics lecturer who lives with his wife. Prior to admission, he performed all 
activities of daily living independently. Before his complaint started, he was a regular jogger 
and only a few years ago was running marathons. Though he had never smoked tobacco, he 
admitted to drinking alcohol in excess several years ago (a maximum of two bottles of wine 
per day). There was no history of neurological or neuromuscular disease in the family. He 
denied any recent illnesses or malaise. 
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On admission, his general examination was unremarkable. Neurological examination 
demonstrated normal power and tone in both limbs (reflexes were not commented on the 
Emergency Department). He was admitted for observation under the medical team. 
 
During the first two days of admission, he had several episodes of confusion and aggression 
towards staff, which was very much out of character, and he experienced visual 
hallucinations, seeing “crawly things.” His fluctuating mental status was attributed to 
delirium caused by a urinary tract infection and was treated as such. His delirium resolved 
within 48 hours. 
 
On day four of admission he was reviewed by spinal surgeons for ongoing back pain. On 
examination, his left lower limb was noted to be weaker than his right: Medical Research 
Council (MRC) 3/5 throughout versus 5/5 throughout on the right. Reflexes were thought to 
be normal throughout. 
 
On day eight of admission he was reviewed by a neurologist who confirmed that his left 
lower limb was weaker than the right and noted that it was predominantly proximal. Some 
upper limb weakness was also observed, while reflexes were documented as normal. 
 
On day 14, increased upper limb weakness was noted by the neurologists. The next day, his 
lower limb weakness was more clearly symmetrical and scored MRC 2/5 distally and 1/5 
proximally for power. There were no sensory abnormalities and lower limb reflexes were 
thought to be symmetrically diminished.  
 
In summary, in the two weeks following admission, the patient’s condition developed from 
back pain and subjective lower limb weakness to asymmetrical and then proximal and 
symmetrical objective weakness. Though he did not complain of upper limb weakness on 
admission, proximal and symmetrical arm weakness developed subsequently. There was no 
sensory abnormality, and reflexes were found to be symmetrically diminished throughout.  
 
Our patient’s condition gradually worsened over the following five weeks until it reached its 
nadir around day 45 of admission. At this point the patient had no movement in his lower 
limbs and had severe bilateral upper limb weakness (MRC 1-2/5). No sensory abnormality 
was detected, though reflexes were symmetrically diminished.  
 
INVESTIGATIONS If relevant 
The initial blood tests demonstrated a leucocytosis of 18.2x10^9/L and a neutrophilia of 
13.4x10^9/L. There was a hyponatremia of 120mmol/L, and CRP was 48. No 
electrocardiogram or chest radiography was performed. 
 
The MRI studies of the spine and spinal cord requested by the spinal surgeons were negative 
for compression of nerve roots and spinal cord, showing only degenerative bony changes, 
and a subtle diffuse low signal from the bony spine which the neuroradiologist’s report 
indicated could be due to a disease process in the bone such as metastasis, myeloma or 
lymphoma.  A month into his admission a repeat MRI with contrast confirmed the original 
report. 
 
There were numerous negative/normal investigations. Blood glucose levels and haematinics 
were normal, which pointed away from neuropathy caused by diabetes mellitus or B12/folate 
deficiency. Creatinine kinase levels were measured several times, peaking at 155 units/L. 
The myeloma screen was normal, as were cerebrospinal fluid cytology, common cancer 
markers (Ca19-9, CEA, AFP) and antineuronal antibodies (anti-Yo, anti-Hu and anti-Ri). A CT 
thorax-abdomen-pelvis detected no malignancy. Other normal or negative tests included: 
ANCA, ANA, urinary porphobilinogen levels, lead levels, urinary organic acids, acetylcholine 
receptor antibodies (myasthenia gravis), ganglioside Q1b antibodies (Miller-Fisher 
syndrome), voltage-gated potassium channel antibodies (encephalitis etc.), antibodies 
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against neurofascin-155, neurofascin-186/140, CASPR/contactin-1 (some subgroups of 
CIDP).  
 
The only positive biochemical investigation was the CSF protein of 1.36 g/L (0.15-0.45g/L). 
 
Finally, nerve conduction studies (NCS) confirmed a mixed motor and sensory demyelinating 
and axonal peripheral neuropathy. According to the European Federation of Neurological 
Societies/Peripheral Nerve Society diagnostic guidelines, we can say our patient has definite 
CIDP. Our patient’s progressive symmetrical proximal and distal weakness which developed 
over months along with reduced tendon reflexes qualify for a diagnosis of typical CIDP. 
Furthermore, because he met none of the exclusion criteria (e.g. prominent sphincter 
disturbance, a diagnosis of multifocal motor neuropathy, etc.), but did meet the relevant 
nerve conduction study criteria, he qualifies for a diagnosis of definite CIDP. The specific 
electrophysiological criteria he meets are the absence of the F-waves in two nerves with 
slow median conduction velocity[1]. Some neurophysiological findings that support the 
diagnosis of definite CIDP are shown in Table 1.  
 
 
 
Table 1: Selected nerve conduction study data showing the specific diagnostic criteria met 
for a definite diagnosis of CIDP. The abnormal data are underlined. The nerve conduction 
study shows normal amplitude median, radial, sural and superficial peroneal sensory action 
potentials but absent ulnar sensory action potential. Where present, the sensory nerve 
conduction velocities are all normal, except for the median nerve which is reduced at 
37.7m/s (should be >40m/s). The motor responses show an absent tibial motor response. 
The median, ulnar and common peroneal distal motor latencies are significantly prolonged. 
The ulnar proximal conduction velocity is normal, but there is slowing of median and 
common peroneal conduction below the lower limit of normal in the forearm and lower leg 
respectively. Both the median and common peroneal compound motor action potentials are 
significantly reduced in amplitude, but the ulnar is within the normal range. The ulnar and 
tibial F-waves are absent, and these two nerves also demonstrate slowed conduction 
velocity, thus satisfying the electrophysiological criteria for a diagnosis of definite CIDP. 
 
Selected Nerve Conduction Study Data 
Sensory Latency (ms) Velocity (m/s) 
Right median nerve 3.45 37.7 
Right ulnar nerve No response 
Right radial nerve 1.70 41.2 
Right sural nerve 3.25 40.0 
Right superior peroneal 
nerve 
4.55 30.8 
Motor   
Right median nerve (wrist) 7.25  
Right median nerve (elbow) 13.40 35.8 
Right ulnar nerve (wrist) 4.05  
Right ulnar nerve (elbow) 8.40 55.2 
Right tibial nerve (knee) No response  
Right common peroneal 
(knee) 
19.00 Too low to accurately 
calculate 
F-wave 
Right ulnar nerve No response  
Right tibial nerve No response  
DIFFERENTIAL DIAGNOSIS If relevant 
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The numerous differential diagnoses were narrowed down to a handful of subacute/chronic 
demyelinating polyneuropathies: subacute/chronic because of the natural history of the 
disease; demyelinating because of the NCS findings; polyneuropathy because clinical 
examination evidenced multiple nerve or nerve root involvement.  
 
Though Guillain-Barré syndrome (GBS) is a demyelinating polyradiculopathy it was ruled out 
because it presents acutely. Systemic causes of demyelinating polyneuropathies (myeloma, 
diabetes) were also been ruled out. Multifocal motor neuropathy was considered, although 
the patient’s symmetrical pattern of weakness did not favour this diagnosis. Motor neurone 
disease, because it is not a demyelinating disease, was excluded by the nerve conduction 
studies.  
 
Two known syndromes fit the all the data: chronic inflammatory demyelinating 
polyneuropathy (CIDP) and multifocal acquired demyelinating sensory and motor (MADSAM) 
neuropathy. MADSAM neuropathy was unlikely because it often affects discrete peripheral 
nerves (rather than roots or plexuses) and our patient had no clinical sensory abnormality. 
Based on his symmetrical, predominantly proximal chronic polyneuropathy of a 
demyelinating character without autonomic involvement, the definitive diagnosis of CIDP 
was made.  
 
TREATMENT If relevant  
 
Our patient underwent two courses of intravenous immunoglobulin (IVIG) therapy. Though 
he recovered some strength, it was difficult to ascertain whether the improvement was 
merely coincidental. However, he demonstrated a clearer response to intravenous 
glucocorticoid therapy (methylprednisolone) and was eventually transferred to a neuro-
rehabilitation hospital with a tapering dose of oral steroids.  
 
OUTCOME AND FOLLOW-UP   
 
Over the three months following diagnosis, the patient gradually regained strength: first 
self-propelling in a wheelchair, then transferring independently. Three months after 
discharge he was able to walk short distances with crutches, though his discharge from the 
rehabilitation unit was delayed several times due to further urinary tract infections and 
hyperglycaemia secondary to steroid therapy. 
 
 
DISCUSSION Include a very brief review of similar published cases  
 
CIDP is a disorder of peripheral nerves and nerve roots. It is one of several diseases and 
syndromes which are characterised by be chronic immune-mediated inflammation, these 
include: Multifocal Motor Neuropathy, MADSAM neuropathy, demyelinating syndromes with 
paraproteins, POEMS syndrome, and demyelinating neuropathy secondary to systemic 
disorders such as infection or diabetes mellitus. [1] 
 
The underlying pathology of CIDP is poorly understood, but it is known to involve both a 
cellular and humoral autoimmunity. [1] Some cases of CIDP are associated with known 
antibodies which target isoforms of neurofascin, a neuronal cytoskeleton protein. A recent 
study has shown that IgG4 responses to NF155 correlate to a treatment-resistant form of 
CIDP which responds to Rituximab in 14% of patients with CIDP. [2] In this case, 
autoantibodies against neurofascin-155, -140 and -186 were negative, as were 
autoantibodies to contactin-1, another antibody implicated in CIDP.  
 
On a medical take, if a patient presents with a fall or leg weakness it is imperative to 
consider neurological causes. Leg weakness rightly prompts immediate concern about spinal 
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cord compression, but other causes should be borne in mind. As our case illustrates, a 
further question which is worth asking is whether the patient could be presenting with a 
neuroinflammatory condition, be it CIDP or perhaps multiple sclerosis. For any such patient, 
a complete lower limb neurological examination (including reflexes and sensation) is 
indispensable. 
 
If a patient’s presentation suggests a neuroinflammatory condition, a further question to 
consider is whether the pattern of weakness is best explained by GBS or CIDP (or something 
else). In GBS the exact point of onset of symptoms can usually be readily identified by the 
patient, whereas this is not the case in CIDP. The progression of symptoms over two to four 
weeks suggests GBS, whereas CIDP will have a slower natural history (more than eight 
weeks from onset to nadir). Usually, prominent sensory signs such as ataxia and impaired 
sensation favour CIDP. Proximal limb weakness favours CIDP, as in the present case, 
whereas GBS classically produces length-dependent ‘ascending paralysis’ affecting the power 
of distal muscles first. (GBS includes acute inflammatory demyelinating polyneuropathy (the 
commonest GBS) but also other variants such as axonal GBS). In CIDP it is common for 
sensory symptoms to dominate the clinical picture. Usually, there is greater impairment in 
vibration and position sense than in pain and temperature sense. Occasionally, painful 
dysesthesias occur. Back pain is a known feature, and signs of spinal stenosis and cord 
compression can occur if there is enough nerve root hypertrophy. Autonomic involvement in 
CIDP is not usually significant, whereas it often is in GBS. [3] 
 
It has been commented that CIDP is over-diagnosed. It is, therefore, worth being aware of 
the chameleons and mimics of CIDP. We have already discussed some CIDP chameleons—
conditions which might at first appear to be CIDP. Mimics are conditions whose signs and 
symptoms suggest CIDP but are in fact due to a different disease process. [4] These mimics 
are associated with red flags which should prompt the formulation of alternative diagnoses 
to CIDP. Such red flags include: prominent pain symptoms, significant muscle aching, no or 
little sensory disturbance, co-morbid conditions and/or systemic features of malignancy, 
cranial nerve involvement (though it is possible to have cranial nerve involvement in CIDP), 
respiratory muscle involvement, head drop, significant autonomic involvement, and failure to 
respond to normal treatment. Some mimics of CIDP not already mentioned include: 
• Genetic mimics e.g. CMT1X  
• POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin 
changes) 
• Paraprotein related neuropathy 
• Amyloid 
• Treatment related fluctuations in GBS 
• Vasculitis 
 
In practice it can be difficult to diagnose CIDP with certainty. Initial presentations can be 
diverse and vague, and there are unusual cases of CIDP which present solely with sensory 
neurology,[5] [6] while other cases display significant nerve root hypertrophy leading to 
compressive pathology. [7] While it is important to rule out spinal cord compression in cases 
of lower limb weakness, primary pathology of the nervous system itself should not merely be 
an afterthought. This favours a good outcome for patients, as there is evidence that IVIG, 
glucocorticoids and plasma exchange that can all provide patients a clinically significant 
benefit. [3] 
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points – this is a required 
field 
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• Signs and symptoms are sometimes dynamic, and need to be monitored closely from 
the point of admission to form an accurate diagnosis 
• CIDP is a rare neurological cause of falls which should be considered in patients with 
proximal and symmetrical weakness and pain as part of a thorough neurological 
assessment 
• There is no definitive autoantibody test for CIDP, though a subgroup of IVIG-resistant 
CIDP is associated with anti-neurofascin antibodies 
• It is important to consider a broad range of differential diagnoses when the clinical 
picture is uncertain 
• Sometimes, CIDP is a diagnosis of exclusion 
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FIGURE/VIDEO CAPTIONS figures should NOT be embedded in this document 
 
 
 
 
 
 
 
 
 
PATIENT’S PERSPECTIVE Optional but strongly encouraged – this has to be written 
by the patient or next of kin 
There is a lot I do not remember about the last few months. I remember feeling 
unwell and being unable to drive at Christmas time, having had backpain for 
months. I finally went to my GP and promptly collapsed on the floor in clinic, 
whereupon he called an ambulance. As I got weaker and weaker in hospital I 
became worried. I could not understand why it was taking so long for the doctors 
to figure out what was wrong with me. Every day as I was waking up I would have 
the same feeling: today will be just like yesterday, and tomorrow will be the same 
again. It was crushing boredom, and I couldn’t get my head around why it was 
taking so long to get a diagnosis. But after a while I drew a line under it all and put 
my whole trust in the doctors—I really had no choice. I remember one neurologist 
telling me, once the diagnosis had been made, that it was a rocky road ahead. It 
certainly has been rocky but I take each day as it comes. I roll today’s boulder out 
of the way and will do the same tomorrow. I’ve never asked ‘why me?’. It’s much 
better to just keep going. I’ve only now started to tell our friends about all this 
because it was too painful to rake it all over. But things are better now, though I 
know we’re not out of the woods yet. 
 
Addendum: the patient sadly died about a year after discharge due to unrelated 
disease. 
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